Aimmune Therapeutics Inc (Aimmune), a subsidiary of Societe Des Produits Nestle SA, is a clinical-stage biopharmaceutical company. It develops proprietary product candidates for the treatment of peanut, gastrointestinal and metabolic-related diseases. The company's product pipeline includes AR101- Peanut Allergy Powder-dnfp (PALFORZIA), used to treat peanut allergy. Its gastrointestinal pipeline products portfolio comprises CDX-7108 for exocrine pancreatic insufficiency, SER-287 and SER-30 ulcerative colitis, and PheFlo (CDX-6114) for phenylketonuria. Aimmune also discovers, develops and commercializes therapies related to food allergy. The company conducts research and development in collaboration with leading biotechnology companies. It operates in the US, Ireland, Germany and the UK. Aimmune is headquartered in New Jersey, the US.
Headquarters
United States of America
Address
Building JR2, Suite E102, 1007 US Highway 202/206, Bridgewater, New Jersey, 08807
Website
www.aimmune.com
Telephone
1 650 6145220
Industry
Pharmaceuticals and Healthcare
Aimmune Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| AR101: Peanut Allergy Powder-DNFP (PALFORZIA) |
| AR601: Multi-Nut Allergy |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Aimmune Therapeutics Inc | Abgent | Eidos Therapeutics Inc | Immunomic Therapeutics Inc | Ridgeback Biotherapeutics LP |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Bridgewater | San Diego | San Francisco | Rockville | Miami |
| State/Province | New Jersey | California | California | Maryland | Florida |
| No. of Employees | - | - | 45 | - | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Andrew Oxtoby | Chief Executive Officer; President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward